A Phase 2 interventional study of Talacotuzumab and Daratumumab in Myelodysplastic Syndromes, sponsored by Janssen Research & Development, LLC. Completed at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Myelodysplastic Syndromes by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Myelodysplastic Syndromes · Johnson & Johnson.
Among the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2017, is one of 8 in phase 2, and was the 16th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →1 of the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Australia, Belgium, Denmark and 12 more countries
Ages 18+
By country, each count listing its studies:
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 62 across the 17 interventional studies, 156 across the 3 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to evaluate the efficacy (transfusion independence [TI]) of talacotuzumab (JNJ-56022473) or daratumumab in transfusion-dependent participants with low or intermediate-1 risk Myelodysplastic Syndrome (MDS) whose disease has relapsed during treatment with or is refractory to Erythropoiesis-Stimulating Agent (ESAs).
This is a multicenter, randomized (study drug assigned by chance), open-label (participants and researchers are aware of the treatment participants are receiving) study to evaluate the safety and efficacy of talacotuzumab or daratumumab. Approximately 60 participants (30 to receive talacotuzumab and 30 to receive daratumumab) will be enrolled and then assigned randomly on a 1:1 basis to receive either talacotuzumab or daratumumab. The study consists of: a Screening Phase of up to 28 days during which participant eligibility will be reviewed and approved by the sponsor prior to randomization, a Treatment Phase that will extend from the first dose on Cycle 1 Day 1 until study drug discontinuation, and a Post-treatment Follow up Phase beginning once the participant discontinues talacotuzumab or daratumumab. Study drugs will continue to be administered until disease progression, lack of response, unacceptable toxicity, withdrawal of consent, or study end. Safety will be monitored throughout the study. The talacotuzumab arm of the study is closed for enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
Drug: Talacotuzumab
Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
Drug: Daratumumab
Talacotuzumab 9 mg/kg will be administered as an IV infusion.
Also known as: JNJ-56022473
Daratumumab 16 mg/kg will be administered as an IV infusion.
Also known as: JNJ-54767414
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks
Percentage of participants who achieved RBC TI lasting at least 8 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
Time frame: Up to 2 years
Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 24 Weeks
Percentage of participants who achieved RBC TI lasting at least 24 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
Time frame: Up to 2 years
Time to Transfusion Independence (TI)
Time to transfusion independence (TI) was defined as time to the start of the TI interval. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
Time frame: Up to 2 years
Duration of Transfusion Independence (TI)
Duration of TI was reported. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
Time frame: Up to 2 years
Percentage of Participants Who Met IWG Criteria for Transfusion Reduction
Percentage of participants who met IWG criteria for transfusion reduction were reported. IWG criteria for transfusion reduction: at least 4 units reduction in RBC transfusions in the best 8-week interval. The best 8-week interval was a post-baseline 8-week interval where the participant had the fewest post-baseline RBC transfusion units.
Time frame: Up to 2 years
Percentage of Participants With at Least One Dose of Myeloid Growth Factors Usage
Percentage of participants with Myeloid Growth Factors (MGF) usage (who had used at least 1 dose of MGF) were reported.
Time frame: Up to 2 years
Percentage of Participants With Hematologic Improvement (HI) Per IWG 2006 by Investigator Assessment
Percentage of participants with HI per International Working Group (IWG) 2006 by investigator assessment were reported. Response criteria per IWG 2006 for HI: Erythroid response (pretreatment, less than \[\<\]11 gram per deciliter \[g/dL\]) - hemoglobin increase by greater than or equal to (\>=)1.5 g/dL, relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hb of \<=9 g/dL pretreatment counted in the RBC transfusion response evaluation; Platelet response (pretreatment, \<100\*10\^9/L) - absolute increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets. Increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100 percent (%); Neutrophil response (pretreatment, \<1\*10\^9/L) - at least 100% increase and an absolute increase \>0.5\*10\^9/L.
Time frame: Up to 2 years
Percentage of Participants With Complete Remission (CR) and Marrow CR
Percentage of participants with CR and marrow CR were reported. CR per International Working Group (IWG) 2006 Response criteria: Bone marrow - less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines, persistent dysplasia noted; Peripheral blood - hemoglobin \>=11 g/dL; platelets \>=100\*10\^9/L; neutrophils \>=1.0\*10\^9/L; blasts, 0%. Marrow CR: Bone marrow - \<=5% myeloblasts and decrease by \>=50% over pretreatment; Peripheral blood - if HI responses, they were noted in addition to marrow CR.
Time frame: Up to 2 years
Percentage of Participants With Partial Remission (PR)
Percentage of participants with PR were reported. PR per International Working Group (IWG) 2006 Response criteria: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5%, cellularity and morphology not relevant.
Time frame: Up to 2 years
Percentage of Participants With Cytogenetic Response
Percentage of participants with cytogenetic response were reported. Cytogenetic response per International Working Group (IWG) 2006 Response criteria: Complete - disappearance of the chromosomal abnormality without appearance of new ones; Partial - at least 50% reduction of the chromosomal abnormality.
Time frame: Up to 2 years
Overall Survival
The overall survival was defined as the time from the date of first dose of study drug to date of death from any cause. Median overall survival was estimated by using the Kaplan-Meier method.
Time frame: Up to 2 years
Time to Progression to Acute Myeloid Leukemia (AML)
Time to progression to acute myeloid leukemia was reported. Disease progression as per IWG response criteria: For participants with: \<5% blasts: \>=50% increase in blasts to \>5% blasts; 5%-10% blasts: \>=50% increase to \>10% blasts; 10%-20% blasts: \>=50% increase to \>20% blasts; 20%-30% blasts: \>=50% increase to \>30% blasts. Any of the following: \>=50% decrement from maximum remission/response in granulocytes or platelets; reduction in hemoglobin by \>=2 g/dL; transfusion dependence.
Time frame: Up to 2 years
Out of 34 enrolled participants, 33 participants received daratumumab and 1 participant received talacotuzumab.
| Milestone | Talacotuzumab | Daratumumab |
|---|---|---|
| Started | 1 | 33 |
| Completed | 0 | 33 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Percentage of participants who achieved RBC TI lasting at least 8 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 8 Weeks | 0 | 6.1 (0.7 to 20.2) |
Percentage of participants who achieved RBC TI lasting at least 24 weeks were reported. RBC TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence (TI) Lasting at Least 24 Weeks | 0 | 3.0 (0.1 to 15.8) |
Time to transfusion independence (TI) was defined as time to the start of the TI interval. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
| Weeks | Talacotuzumab | Daratumumab |
|---|---|---|
| Participant 1 | — | 4 |
| Participant 2 | — | 5 |
| Participant 3 | NA | — |
Duration of TI was reported. TI was defined as absence of RBC transfusion during any consecutive 56 days (8 weeks) post randomization.
| Weeks | Talacotuzumab | Daratumumab |
|---|---|---|
| Participant 1 | — | 16 |
| Participant 2 | — | 65 |
| Participant 3 | NA | — |
Percentage of participants who met IWG criteria for transfusion reduction were reported. IWG criteria for transfusion reduction: at least 4 units reduction in RBC transfusions in the best 8-week interval. The best 8-week interval was a post-baseline 8-week interval where the participant had the fewest post-baseline RBC transfusion units.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Percentage of Participants Who Met IWG Criteria for Transfusion Reduction | 0 | 54.5 |
Percentage of participants with Myeloid Growth Factors (MGF) usage (who had used at least 1 dose of MGF) were reported.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Percentage of Participants With at Least One Dose of Myeloid Growth Factors Usage | 0 | 9.1 |
Percentage of participants with HI per International Working Group (IWG) 2006 by investigator assessment were reported. Response criteria per IWG 2006 for HI: Erythroid response (pretreatment, less than \[\<\]11 gram per deciliter \[g/dL\]) - hemoglobin increase by greater than or equal to (\>=)1.5 g/dL, relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 weeks compared with the pretreatment transfusion number in the previous 8 weeks. Only RBC transfusions given for a Hb of \<=9 g/dL pretreatment counted in the RBC transfusion response evaluation; Platelet response (pretreatment, \<100\*10\^9/L) - absolute increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets. Increase from \<20\*10\^9/L to \>20\*10\^9/L and by at least 100 percent (%); Neutrophil response (pretreatment, \<1\*10\^9/L) - at least 100% increase and an absolute increase \>0.5\*10\^9/L.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Erythroid Response | 0 | 9.1 (1.9 to 24.3) |
| Platelet Response | 0 | 0.0 (0.0 to 10.6) |
| Neutrophil Response | 0 | 0.0 (0.0 to 10.6) |
Percentage of participants with CR and marrow CR were reported. CR per International Working Group (IWG) 2006 Response criteria: Bone marrow - less than or equal to (\<=)5% myeloblasts with normal maturation of all cell lines, persistent dysplasia noted; Peripheral blood - hemoglobin \>=11 g/dL; platelets \>=100\*10\^9/L; neutrophils \>=1.0\*10\^9/L; blasts, 0%. Marrow CR: Bone marrow - \<=5% myeloblasts and decrease by \>=50% over pretreatment; Peripheral blood - if HI responses, they were noted in addition to marrow CR.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Complete Remission (CR) | 0 | 0 |
| Marrow CR | 0 | 3.0 |
Percentage of participants with PR were reported. PR per International Working Group (IWG) 2006 Response criteria: All CR criteria if abnormal before treatment except: Bone marrow blasts decreased by \>=50% over pretreatment but still \>5%, cellularity and morphology not relevant.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Percentage of Participants With Partial Remission (PR) | 0 | 0 |
Percentage of participants with cytogenetic response were reported. Cytogenetic response per International Working Group (IWG) 2006 Response criteria: Complete - disappearance of the chromosomal abnormality without appearance of new ones; Partial - at least 50% reduction of the chromosomal abnormality.
| Percentage of participants | Talacotuzumab | Daratumumab |
|---|---|---|
| Percentage of Participants With Cytogenetic Response | 0 | 0 |
The overall survival was defined as the time from the date of first dose of study drug to date of death from any cause. Median overall survival was estimated by using the Kaplan-Meier method.
| Months | Talacotuzumab | Daratumumab |
|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) |
Time to progression to acute myeloid leukemia was reported. Disease progression as per IWG response criteria: For participants with: \<5% blasts: \>=50% increase in blasts to \>5% blasts; 5%-10% blasts: \>=50% increase to \>10% blasts; 10%-20% blasts: \>=50% increase to \>20% blasts; 20%-30% blasts: \>=50% increase to \>30% blasts. Any of the following: \>=50% decrement from maximum remission/response in granulocytes or platelets; reduction in hemoglobin by \>=2 g/dL; transfusion dependence.
| Weeks | Talacotuzumab | Daratumumab |
|---|---|---|
| Time to Progression to Acute Myeloid Leukemia (AML) | NA (NA to NA) | NA (54.7 to NA) |
Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Talacotuzumab | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Daratumumab | 6/33 (18.2%) | 15/33 (45.5%) | 33/33 (100%) |
| Event | Talacotuzumab | Daratumumab |
|---|---|---|
| Metabolic AcidosisMetabolism and nutrition disorders | 1/1 | 0/33 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/1 | 0/33 |
| PyrexiaGeneral disorders | 0/1 | 3/33 |
| PneumoniaInfections and infestations | 0/1 | 3/33 |
| Acute Coronary SyndromeCardiac disorders | 0/1 | 1/33 |
| Atrial FibrillationCardiac disorders | 0/1 | 1/33 |
| Cardiac FailureCardiac disorders | 0/1 | 1/33 |
| Cardiac Failure CongestiveCardiac disorders | 0/1 | 1/33 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/33 |
| Rectal HaemorrhageGastrointestinal disorders | 0/1 | 1/33 |
| Event | Talacotuzumab | Daratumumab |
|---|---|---|
| NauseaGastrointestinal disorders | 1/1 | 3/33 |
| VomitingGastrointestinal disorders | 1/1 | 3/33 |
| Renal ImpairmentRenal and urinary disorders | 1/1 | 0/33 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 1/1 | 0/33 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/1 | 9/33 |
| PyrexiaGeneral disorders | 0/1 | 8/33 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 7/33 |
| AnaemiaBlood and lymphatic system disorders | 0/1 | 6/33 |
| NeutropeniaBlood and lymphatic system disorders | 0/1 | 6/33 |
| AstheniaGeneral disorders | 0/1 | 6/33 |
| Age, Continuous(years) | Talacotuzumab | Daratumumab | Total |
|---|---|---|---|
| Mean | 67 | 71.5 ± 6.86 | 71.4 ± 6.8 |
| Sex: Female, Male(Participants) | Talacotuzumab | Daratumumab | Total |
|---|---|---|---|
| Female | 0 | 8 | 8 |
| Male | 1 | 25 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Talacotuzumab | Daratumumab | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 4 |
| Not Hispanic or Latino | 1 | 27 | 28 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Talacotuzumab | Daratumumab | Total |
|---|---|---|---|
| Other | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 3 | 3 |
| White | 1 | 29 | 30 |
| Region of Enrollment(Participants) | Talacotuzumab | Daratumumab | Total |
|---|---|---|---|
| BELGIUM | 1 | 6 | 7 |
| ITALY | 0 | 3 | 3 |
| NETHERLANDS | 0 | 3 | 3 |
| RUSSIAN FEDERATION | 0 | 3 | 3 |
| SPAIN | 0 | 10 | 10 |
| UNITED STATES | 0 | 8 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Jan 2019, 23 months.
Results were first posted in Mar 2020, 1 year 1 month after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 23 months is below that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Talacotuzumab · Daratumumab
Janssen Research & Development, LLC →